What Pfizer, Trump, and consumers got out of a surprising deal — and what they didn’t
From the article:
After months of pledging he would get pharmaceutical companies to lower their prices, President Trump can now say that he pressed the CEO of a major drug maker, Pfizer, to back down on a series of price hikes.
Pfizer, in turn, has earned glowing praise from Trump and his administration and will likely not suffer much, if at all, financially.
Read more here!fda health care finance health law policy pharmaceuticals rachel sachs